HeartBeam (NASDAQ: BEAT) announced its synthesized 12-lead ECG met clinical endpoints in the VALID-ECG pivotal study, achieving 93.4% diagnostic agreement with standard ECGs for arrhythmia assessment.

HeartBeam (Nasdaq:BEAT) today announced that a study of its synthesized 12-lead electrocardiogram (ECG) met its clinical endpoints.

This paper investigates the design of both hardware and software for a 12-lead mobile electrocardiogram (ECG) monitoring system. The 12-lead ECG captures the heart's electrical activity from multiple ...

In order to further reduce the amplitudes of the P and T waves, the ECG signal is shifted towards the negative part of the Y-axis proportional to its average standard deviation. The QRS candidates of ...

The British publisher Tilted Axis specialized in innovative translated literature. It won them major awards. Now they’re coming to the U.S.

The Company is creating the first ever cable-free synthesized 12-lead ECG capable of capturing the heart’s electrical signals from three distinct directions.

AliveCor announced that CMS included its AI-powered ECG system in a final rule that sets a Medicare payment rate for the technology.

Overall, the results indicate the Kardia 12L ECG System's ability to maintain robust diagnostic accuracy for most major morphology classes. "The study surpassed our expectations, showing that the ...

Twelve of the 36 cinnamon powders and spice blends containing cinnamon had high levels of lead, according to Consumer Reports' testing.

The study will also examine the accuracy of physician diagnosis for various arrhythmias with the AIMIGo synthesized 12-lead ECG, compared to a standard 12-lead ECG.